AMD Clinical Trial
Official title:
A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Participants With Neovascular Age-Related Macular Degeneration
This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal space (SCS) administration of RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for up to 5 years after RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following RGX-314 administration in the parent study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
| Recruiting |
NCT03893474 -
Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners
|
N/A | |
| Completed |
NCT00971464 -
Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation
|
Phase 2 | |
| Terminated |
NCT00332657 -
Anecortave Acetate Risk Reduction Trial (AART)
|
Phase 3 | |
| Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
| Active, not recruiting |
NCT01766596 -
Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)
|
N/A | |
| Completed |
NCT03322930 -
Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
|
||
| Completed |
NCT01778491 -
AMD Phenotype and Genotype Study
|
||
| Completed |
NCT01016873 -
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
|
Phase 2 | |
| Active, not recruiting |
NCT03845582 -
Phase 3 Study of ALK-001 in Geographic Atrophy
|
Phase 3 | |
| Completed |
NCT03367767 -
Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
|
||
| Completed |
NCT03372746 -
Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
|
||
| Terminated |
NCT00333216 -
Anecortave Acetate Risk-Reduction Trial (AART)
|
Phase 3 | |
| Completed |
NCT01570790 -
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Completed |
NCT00346866 -
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
|
Phase 2 | |
| Withdrawn |
NCT00726466 -
Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
|
Phase 1 | |
| Completed |
NCT00306488 -
OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration
|
Phase 2 | |
| Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT01632527 -
Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01339949 -
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
|
N/A |